Work

Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz420.003

Authors: F. de Braud, S. Siena, F. Barlesi, A. Drilon, B. Simmons, X. Huang, S. Osborne, R.C. Doebele

Institutions: University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Memorial Sloan Kettering Cancer Center, Genentech

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Eli Lilly and Company, Pfizer, AstraZeneca, Ariad Pharmaceuticals, Celgene, Genomic Health, AstraZeneca Canada, Regeneron Pharmaceuticals, Ipsen, Genentech, Chugai Pharmaceutical, Pfizer Canada, Ignyta

OpenAlex ID: W4229972308

FWCI:

Cites:

Cited by:

Related to: 10